Fairbanks Presents at Endocrine Society Annual Meeting

Fairbanks Pharmaceuticals CEO Alan Schneyer presents at Endocrine Society 2018 annual meeting
The Endocrine Society held its Annual Meeting in Chicago March 17-20th, 2018.  A major focus of endocrinology involves metabolism and diabetes and Fairbanks Pharmaceuticals CEO Alan Schneyer presented the progress achieved by Fairbanks Pharmaceuticals in developing a new diabetes therapy in a poster on Monday March 19th.

In the poster he described the scientific basis for the therapeutic strategy of neutralizing FSTL3, development of antibodies that can achieve this goal, and initial testing showing promise on diabetic mouse islets.

In recognition of its strength and uniqueness, the poster was selected for a new activity where top posters are presented orally to an assembled group of scientists during the poster session.  The response to this therapeutic was positive and encouraging and we look forward to continuing the development program with in vivo studies in the near future.